Sean Brynjelsen serves as Executive at Sagent Pharmaceuticals, Inc., where they oversee executive responsibilities. Since joining the company, Sean Brynjelsen has executed 11 insider transactions totaling $264.1K, demonstrating a bullish approach to their equity position. Their most recent transaction on Dec 12, 2025 involved selling 6,732 shares valued at $113.3K.
Sean Brynjelsen currently holds 2,894,281 shares of Sagent Pharmaceuticals, Inc. (SGNT), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sean Brynjelsen has been a net buyer of SGNT stock. They have purchased $264.1K and sold $0 worth of shares.
Sean Brynjelsen's most recent insider trade was on Dec 12, 2025, when they sold 6,732 shares at $16.83 per share.
Get notified when new Form 4 filings are submitted
| $2.10 |
| Discretionary |
| Aug 20, 2021 | ETON | $43.2K | Purchase | 10,000 | $4.32 | Discretionary |
| Jun 3, 2021 | ETON | $29.8K | Purchase | 5,000 | $5.96 | Discretionary |
| Aug 13, 2019 | ETON | $30.8K | Purchase | 5,000 | $6.15 | Discretionary |
| May 21, 2019 | ETON | $68.5K | Purchase | 8,600 | $7.96 | Discretionary |
| May 20, 2019 | ETON | $10.9K | Purchase | 1,400 | $7.78 | Discretionary |
| Nov 15, 2018 | ETON | $60.0K | Purchase | 10,000 | $6.00 | Discretionary |
| Nov 15, 2018 | ETON | $0 | Conversion | 24,940 | $N/A | Discretionary |
| Aug 29, 2016 | SGNT | $214.1K | Disposition | 9,844 | $21.75 | Discretionary |
| Apr 4, 2016 | SGNT | $0 | Award | 9,844 | $N/A | Discretionary |